Daily Digest

The Valve Wire

Friday, May 22, 2026

Executive Summary

Today's edition is dominated by the boundary-testing of transcatheter therapy: an advocacy push to expand TAVR access drew a sharp policy rebuke, Boston Scientific committed a striking $1.5 billion to MiRus to challenge the Edwards–Medtronic TAVR duopoly, and the FDA cleared a next-generation mitral valve. In Europe, the FAITAVI debate took aim at routine FFR-guided revascularization before TAVI, while a women-only TAVR trial reinforced advantages of self-expanding platforms. New registry data on transcatheter tricuspid valve replacement continued to highlight dramatic symptom benefit — alongside humbling complications including platypnea–orthodeoxia and the need for staged repair-then-replacement strategies in extreme anatomies.

For the clinical reader: nothing today rises to the level of a guideline-changing RCT, but the news cycle reveals the structural-heart ecosystem in transition. The center of gravity is shifting toward simpler procedures (fast-track TAVI consensus from Poland), broader patient populations (advocacy-led expansion, congenital AS), and an increasingly crowded device landscape (MiRus capital infusion, JenaValve's ARTIST trial enrolling, InnovHeart's SATURN TMVR advancing). The countervailing signals — a 9.7% 30-day TAVI readmission rate with 3-fold mortality penalty, undetectable early hemodynamic valve deterioration, and an editorial in EHJ openly questioning whether routine FFR before TAVI is "one step too far" — are exactly the kind of friction the field needs. As always, we read with one eye on the press release and one on the limitations section.

Today's Key Findings

[NOTABLE] Early rehospitalization after TAVI occurred in 9.7% of 1,347 patients, with a 3-fold higher 1-year mortality (HR 3.03). Modifiable predictors: contrast volume, ≥mild paravalvular leak, and conduction abnormalities at discharge.
Neurological events after TAVI — particularly those occurring beyond 30 days — substantially shorten 2-year survival, with later events showing a steeper prognostic gradient (n=10,079, European multicenter registry).
Boston Scientific announced a $1.5 billion investment in MiRus to advance novel TAVR technology — a direct challenge to the Edwards–Medtronic duopoly.
FDA cleared a next-generation mitral valve (per Cardiovascular Business; specifics emerging).
Same-day discharge after M-TEER appears safe in Medicare data (n=12,048), though only 1.1% of patients were managed this way.
Audiovisual distraction during M-TEER reduced propofol requirements by ~22% in a small RCT (n=60) — a low-tech, sedation-sparing tool.

Aortic Valve (TAVR/TAVI)

[NOTABLE] Early rehospitalization carries a major mortality signal. Alexiou and colleagues retrospectively analyzed 1,347 consecutive TAVI patients in Open Heart and identified a 9.7% 30-day readmission rate, most commonly from infection (22.9%), heart failure (19.8%), and bradycardia (9.9%). Independent predictors included chronic HF, COPD, contrast volume (per 25 mL), ≥mild paravalvular leak, and discharge conduction abnormalities. After adjustment, 1-year mortality was tripled (HR 3.03). Importantly, early (≤2-day) discharge was not a risk factor — supporting the simplified TAVI movement, though noting selection bias is unavoidable in retrospective data. The clinical message is that the post-discharge window deserves the kind of structured surveillance we apply to heart failure and post-MI populations.

Timing of neurological events matters. In the 10,079-patient TRITAVI registry (Tartaglia et al., Can J Cardiol), 2.6% experienced post-TAVI neurological events; 35% occurred beyond 30 days, and these later events were associated with markedly worse survival (-360 days vs -165 days for periprocedural events). Fatal stroke accounted for 40% of non-periprocedural events versus only 6% of early events — a stark reminder that embolic protection has focused almost entirely on the wrong window. Long-term antithrombotic strategies after TAVI remain an open question that NCT06168370 (CT-guided personalized antithrombotic strategy) may help answer.

FAITAVI sparks a productive disagreement. Dueling EHJ editorials from Aarts/Delewi/Voskuil and Ribichini/Pesarini/Tarantini debate whether routine FFR-guided revascularization in TAVI candidates is overreach. TCTMD's coverage of the trial frames PCI before TAVI as offering "only modest benefit." Microvascular disease, altered post-TAVI hemodynamics, and the difficulty of interpreting FFR in severe AS all complicate translation from chronic CAD populations. The pragmatic take: selective, ischemia-driven PCI remains reasonable; routine FFR in this population is not yet evidence-based.

Women-only TAVR data favor self-expanding valves. Per MedPage Today, a sex-specific trial reinforces emerging signals that small annular anatomy — disproportionately found in women — favors supra-annular self-expanding designs for hemodynamics and PPM avoidance. Caveat: device-specific trials sponsored by manufacturers warrant cautious interpretation, particularly when surgical alternatives with annular enlargement remain underutilized in younger women.

Hemodynamic valve deterioration may be silent. A new analysis covered by TCTMD suggests early hemodynamic valve deterioration after TAVI may evade routine echocardiographic surveillance — reinforcing concerns raised in this newsletter previously about durability methodology and the limits of comparing TAVI and SAVR SVD rates at face value. The ESC 2025 guidelines' enthusiasm for comparable durability at 10 years deserves continued skepticism, particularly outside high-volume reporting centers.

Practical case reports. The literature today is rich with cautionary tales: a balloon rupture during direct deployment in heavily calcified anatomy, the use of the UNICORN leaflet modification technique in a 26-year-old with congenital AS, embolization of native leaflet calcium causing acute mesenteric ischemia in a 96-year-old, and Impella-induced torrential AR after BAV requiring bailout TAVI. A pair of EP cases (intermittent LBBB, PR alternans) further emphasize how post-TAVI conduction abnormalities can mask malignant disease. Polish interventionalists also published a useful expert consensus on simplified TAVI in Kardiologia Polska.

Mitral Valve (MitraClip, PASCAL, TMVR)

FDA approves next-gen mitral valve. Per Cardiovascular Business, a next-generation mitral valve received FDA clearance — details on indication breadth, anatomy requirements, and labeling will be the determining factor for adoption. The TMVR space remains characterized by extraordinary anatomic variability between patients and incremental device iteration; few patients have been treated outside trials, and the field has yet to deliver a clear "MitraClip moment" for replacement.

Same-day discharge after M-TEER appears safe — but rarely used. Watanabe et al. in J Cardiol analyzed 12,048 Medicare patients (2016–2021); only 1.1% were discharged same-day, with no significant difference in 30-day mortality or HF readmission versus next-day discharge. This is hypothesis-generating, not practice-changing: same-day discharge was almost certainly applied to highly selected patients, and the absolute event rate (and CI width) prohibits firm conclusions. The findings parallel the simplified-TAVI narrative — operational efficiency may be achievable in a carefully chosen subset.

Audiovisual distraction reduces sedation needs. In a single-center RCT of 60 patients (Rawish et al., JACC Advances), video glasses with nature documentaries reduced propofol requirements (4.6 vs 5.9 mg/kg/h, p=0.002) and improved patient-reported anxiety and satisfaction during M-TEER. Norepinephrine use trended lower but did not reach significance. A small but elegant trial; broader applicability across structural heart procedures merits study.

Transseptal TMVR in Europe. TCTMD reports encouraging European experience with transseptal TMVR — a meaningful procedural simplification versus transapical access. Single-arm registries cannot answer the right question (vs surgery, vs TEER for repairable anatomy), but the procedural feasibility data are accumulating.

The InnovHeart SATURN TMVR trial remains in recruitment, and the US CASSINI-US early feasibility study is gearing up — yet another transseptal entry into a crowded but unproven landscape.

Tricuspid Valve (TriClip, TTVR)

The TTVR symptom story is compelling — but complications continue to teach. Two cases illustrate the spectrum. Marek-Iannucci et al. (JACC Case Rep) describe rapid renal and clinical recovery after EVOQUE TTVR in an 85-year-old with torrential TR — the precise scenario for which ESC 2025 created its IIa recommendation. Nguyen et al. (JACC Case Rep) describe a novel complication: platypnea–orthodeoxia syndrome from acute right-atrial geometric changes unmasking a PFO, requiring percutaneous closure. As TTVR moves into broader practice, operators should anticipate and screen for hemodynamic shunting in patients with persistent hypoxia post-procedure.

ANTARCTIC: staged TEER-then-replacement for extreme annular dilation. Jabri et al. (JACC Case Rep) describe an 85-year-old in whom annular size precluded primary TTVR; PASCAL TEER reduced TR and remodeled the annulus, enabling subsequent EVOQUE 56-mm implantation. Creative, but raises real questions about patient selection and the marginal cost-effectiveness of staged transcatheter procedures in this population versus accepting palliative medical therapy.

Context: These case reports must be read alongside the STS/ACC TVT Registry data we covered previously (98.4% technical success, 3.1% 30-day mortality, but 15.9% new pacemakers). The ESC 2025 Class IIa for transcatheter TR therapy is built on TRILUMINATE, Tri.Fr, and TRISCEND II — trials driven by QoL and HF hospitalization endpoints, not mortality. The case literature is doing important work surfacing the complications the trials are underpowered to characterize.

Trial pipeline: MonarQ (inQB8 TTVR system) is recruiting 50 patients, and the bRIGHT TriClip real-world registry has closed enrollment at 511.

Surgical vs. Transcatheter Comparisons

Two large European randomized trials remain in enrollment that will eventually inform the SAVR-vs-TAVI and surgery-vs-TEER debates beyond industry-sponsored comparisons: NCT05261204 (4,000-patient TAVI vs SAVR) and NCT05090540 (TEER vs surgical replacement vs restrictive annuloplasty for secondary MR, n=600) — both sponsored by Centre Cardiologique du Nord. These investigator-initiated designs are exactly what the field needs to counterbalance industry-driven evidence generation. The JenaValve ARTIST trial (Trilogy TAVR vs SAVR for aortic regurgitation, n=1,016) is another important head-to-head that, if positive, would push ESC 2025's IIb recommendation for TAVI in AR up the ladder.

The 2020 ACC/AHA framework — SAVR-preferred under 65, shared decision 65–80, TAVI-preferred over 80 — looks increasingly out of step with the ESC 2025 lowering the TAVI-preferred threshold to 70. Today's news contained no data shifting that landscape, but the durability uncertainty signal from new hemodynamic deterioration reporting should temper enthusiasm for further age-threshold lowering until 10–15 year data mature.

Preprint Highlights

No structural-heart preprints of note today. (One non-relevant plant virology preprint appeared in the feed and has been filtered.)

Device & Technology

[NOTABLE] Boston Scientific commits $1.5B to MiRus. Per Pulse 2.0, Boston Scientific is investing $1.5 billion in MiRus to develop novel TAVR technology. MiRus has been working on a molybdenum-rhenium alloy frame designed to enable thinner-strut, lower-profile valves. This is a meaningful capital deployment into a duopoly-dominated market (Edwards SAPIEN, Medtronic Evolut) and underscores Boston Scientific's pivot toward structural heart as a growth pillar following the LOTUS withdrawal years ago. Whether the engineering advantage translates into clinical differentiation will require comparative trials BSX has not yet announced.

Edwards' SAPIEN X4 platform continues to enroll in the ALLIANCE study (n=1,234), and Medtronic's Evolut EXPAND TAVR II pivotal trial in moderate AS is now ACTIVE_NOT_RECRUITING — pending readout that could test the boundaries of TAVI indication creep into moderate disease.

Regulatory & Policy

Advocacy push for TAVR access expansion. A patient-advocacy group has urged the Trump administration to revise the National Coverage Determination for TAVR, arguing CMS-required site volumes and dual-operator requirements are restricting patient access. Per Cardiovascular Business, the campaign frames the restrictions as government overreach. The countervailing perspective — and one we believe deserves equal volume — is that volume thresholds protect patients in a procedure where complication rates correlate strongly with operator and program experience. The history of structural heart in the US (TAVR, TMVR, TEER, TTVR) suggests indication creep follows access expansion. Removing volume floors without parallel quality safeguards risks worse outcomes in the patients advocacy groups seek to help. Critics including Badhwar, Chikwe, and others have repeatedly cautioned that volume-outcome relationships in structural heart are real and non-negotiable.

The Polish ACVI expert consensus on simplified TAVI takes the opposite tack — operationalizing efficiency within a quality framework, with explicit procedural standards. That's a more defensible model.

Industry & Market

The structural-heart industry is bifurcating. On one end: incumbents (Edwards, Medtronic, Abbott) defending core franchises while building out tricuspid and TMVR portfolios. On the other: well-capitalized challengers (MiRus, JenaValve, Anteris, InnovHeart, inQB8) developing differentiated platforms with backing from strategics or sustained equity raises. The Boston Scientific–MiRus deal is the most concrete sign yet that the $7B+ TAVR market remains contested, not consolidated.

A separate cultural inflection point: David Letterman has launched a heart valve failure awareness campaign — meaningful for under-screening of valve disease but also a reminder that celebrity advocacy can drive volume into a system whose evidence base for early intervention remains contested.

Financial Analysis

Today's financial picture for the structural heart sector reflects a stark divergence between transcatheter-pure-play stories and broader medtech conglomerates. Edwards Lifesciences has been relatively resilient, down only 1.8% over six months despite ongoing competitive pressure in TAVR and growing scrutiny over TMVR readiness; PNC and Fideuram Intesa Sanpaolo institutional position changes (per MarketBeat) reflect typical rebalancing rather than thesis change. Q2 earnings on July 23 (EPS $0.74 est., revenue $1.70B est.) will be the next major catalyst.

The bigger story is Boston Scientific, down 41.7% over six months — a remarkable drawdown given the company's strong PFA franchise. Today's $1.5B MiRus investment may help reframe the structural heart narrative, but absorption of that capital commitment alongside ongoing M&A appetite is likely contributing to investor concern about ROIC. Analyst consensus remains a strong buy with an $83 target — suggesting Wall Street still sees the multi-franchise growth story intact, but valuation has compressed meaningfully. Medtronic (-23%) and Abbott (-30%) reflect broader healthcare sector weakness compounded by ongoing tariff and reimbursement uncertainty rather than valve-specific issues.

The standout: Anteris Technologies (AVR.AX), up 132.6% in six months, with a fresh 52-week high. The DurAVR platform's clinical trajectory — if data continue to support hemodynamic claims of more physiologic flow profiles — could position Anteris as a credible second-wave TAVR entrant. With a single analyst covering the name, however, the price action reflects narrative momentum more than consensus institutional conviction.

Valve Industry Stocks

6-Month Valve Industry Stock Performance

Edwards Lifesciences (EW)

EW 6-Month Chart

Price: $83.20 (+0.28%); 6-month: -1.78%
Market cap: $47.9B | P/E (TTM): 44.97 | Forward P/E: 24.74 | Beta: 0.87
52-week range: $72.30 – $87.89
Analyst target: $97.15 (range $84–$110, 27 analysts) — Buy
Next earnings: July 23, 2026 (EPS est. $0.74; revenue est. $1.70B)
Commentary: Edwards remains the structural-heart bellwether. SAPIEN X4 readouts from ALLIANCE and ongoing EVOQUE TTVR commercialization are the key catalysts. The Boston Scientific–MiRus deal puts incremental competitive pressure on the TAVR franchise but does not change the near-term economics.

Medtronic (MDT)

MDT 6-Month Chart

Price: $78.15 (flat); 6-month: -23.1%
Market cap: $100.3B | P/E (TTM): 21.83 | Forward P/E: 12.9 | Beta: 0.63
52-week range: $74.40 – $106.33
Analyst target: $108.00 (range $90–$121, 25 analysts) — Buy
Next earnings: June 3, 2026 (EPS est. $1.56; revenue est. $9.61B)
Commentary: Significant 6-month underperformance. Evolut EXPAND TAVR II readout in moderate AS is the structural-heart catalyst worth tracking; Intrepid TMVR enrollment continues at scale (1,056 target).

Abbott Laboratories (ABT)

ABT 6-Month Chart

Price: $87.77 (-0.69%); 6-month: -30.2%
Market cap: $152.9B | P/E (TTM): 24.59 | Forward P/E: 14.47 | Beta: 0.65
52-week range: $81.97 – $139.06
Analyst target: $118.64 (range $92–$143, 25 analysts) — Buy
Next earnings: July 16, 2026 (EPS est. $1.28; revenue est. $12.53B)
Commentary: MitraClip remains the franchise anchor; TriClip is gaining post-approval but real-world reimbursement and access remain bottlenecks. REPAIR-MR readout (n=500) will be a major catalyst for the primary MR indication expansion.

Boston Scientific (BSX)

BSX 6-Month Chart

Price: $57.15 (+0.85%); 6-month: -41.7%
Market cap: $84.9B | P/E (TTM): 23.91 | Forward P/E: 15.19 | Beta: 0.62
52-week range: $52.52 – $109.50
Analyst target: $83.47 (range $60–$106, 32 analysts) — Strong Buy
Next earnings: July 29, 2026 (EPS est. $0.83; revenue est. $5.40B)
Commentary: Today's $1.5B MiRus investment marks BSX's most ambitious structural-heart commitment since the LOTUS Edge withdrawal. Steep stock decline despite strong PFA franchise performance suggests broader portfolio concerns. The strong-buy consensus with substantial upside to target suggests Wall Street sees today's price as a structural opportunity.

Anteris Technologies (AVR.AX)

AVR.AX 6-Month Chart

Price: A$12.91 (+2.95%); 6-month: +132.6%
Market cap: A$1.3B | Forward P/E: -5.92 | Beta: 0.59
52-week range: A$4.68 – A$13.01
Analyst target: A$13.00 (1 analyst)
Commentary: DurAVR remains the differentiated narrative. The stock is trading at fresh highs and at analyst target — clinical execution from here matters more than thesis.

Market outlook: Today's session captures a structural heart industry in transition. Capital is flowing toward novel platforms (MiRus, Anteris) and pivoting away from incumbents whose growth-stock multiples have compressed (BSX, ABT, MDT). The next earnings cycle — Medtronic on June 3, then Edwards, Abbott, and BSX in July — will test whether structural heart can re-emerge as a growth engine after a difficult six months.

Clinical Trial Updates

Active trials updated this week, grouped by valve position:

Aortic

NCT02701283 [LANDMARK] — Evolut Low Risk (long-term follow-up): Active, not recruiting. n=2,223. Sponsor: Medtronic. The mature 10-year readouts from this trial and PARTNER 3 will be foundational for the next ACC/AHA guideline revision and the ongoing TAVI age-threshold debate.
NCT06608823 — ARTIST (Trilogy TAVR vs SAVR for AR): Recruiting. n=1,016. Sponsor: JenaValve. The first major head-to-head for TAVR in aortic regurgitation; if positive, could move ESC 2025's IIb recommendation up.
NCT05149755 — Evolut EXPAND TAVR II Pivotal: Active, not recruiting. n=650. Sponsor: Medtronic. TAVI for moderate AS — the indication-creep trial to watch.
NCT05172960 — ALLIANCE (SAPIEN X4): Active, not recruiting. n=1,234. Sponsor: Edwards.
NCT05261204 — TAVI vs Standard SAVR: Enrolling by invitation. n=4,000. Sponsor: Centre Cardiologique du Nord. Investigator-initiated.
NCT05774691 — POPular ACE TAVI (protamine reversal): Completed. n=1,000.
NCT06168370 — CT-guided antithrombotic strategy post-TAVI: Recruiting. n=2,500. Sponsor: St. Antonius Hospital.
NCT05758662 — POPular PET TAVI (leaflet thrombosis): Recruiting. n=180.
NCT07276711 — CAPTURE-2 (EmStop embolic protection vs Sentinel): Recruiting. n=663.
NCT03728049 — vWF point-of-care testing in minimalist TAVI: Recruiting. n=944.

Mitral Repair

NCT04198870 [LANDMARK] — REPAIR-MR (MitraClip vs surgery for primary MR): Active, not recruiting. n=500. Sponsor: Abbott. The single most important pending trial in primary MR — will inform whether ACC/AHA Class IIa for TEER in high-risk PMR can move further.
NCT05051033 [LANDMARK] — PRIMATY: Recruiting. n=450. Tests TEER vs surgery in PMR patients >60. Critical for the under-70 age cohort where ESC 2025 still favors surgery.
NCT03706833 [LANDMARK] — COAPT long-term follow-up: Active, not recruiting. n=1,247.
NCT05090540 — Transcatheter vs surgical MV for secondary MR: Enrolling by invitation. n=600.
NCT07301151 — PASCAL Feasibility Study: Not yet recruiting. n=120.

Social & Conference Highlights

The community conversation today centers on three threads: (1) the appropriate boundaries of TAVR coverage and indications, sparked by the advocacy push for NCD revision; (2) the MiRus deal and what it signals about competitive intensity in TAVR; and (3) ongoing skepticism about whether FFR-guided revascularization in TAVI candidates is supported by trial data. A useful counterweight to enthusiasm: the EHJ editorials suggesting "one step too far" for routine FFR pre-TAVI represent exactly the kind of guideline-tempered analysis the field needs more of.

Closing Thought

Today's news cycle is a microcosm of structural heart in 2026: capital chasing the next platform, patient advocacy testing access boundaries, and an evidence base trying to keep up with both. Tomorrow's readers should watch the Medtronic earnings call on June 3 for guidance on Evolut EXPAND TAVR II timing — and continue to read every favorable transcatheter readout with the limitations section open.

— E. Nolan Beckett, The Valve Wire

← May 21, 2026